• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Pediatrix (MD) Is Down 8.3% After Profitability Rebound And 2026 EBITDA Outlook Update

    Simply Wall St·02/24/2026 00:28:59
    Listen to the news
    • Pediatrix Medical Group reported past fourth-quarter 2025 sales of US$493.77 million versus US$502.36 million a year earlier, with diluted EPS from continuing operations rising to US$0.40 and full-year 2025 net income improving to US$165.39 million on revenue of US$1.91 billion.
    • The company’s return to full-year profitability followed a major shift toward core hospital-based neonatology and maternal-fetal services, supported by practice disposals, higher same-unit revenue, and renewed emphasis on share repurchases.
    • We’ll now examine how this profitability rebound, alongside 2026 adjusted EBITDA guidance of US$280 million to US$300 million, affects Pediatrix’s investment narrative.

    This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

    Pediatrix Medical Group Investment Narrative Recap

    To own Pediatrix today, you need to believe its tighter focus on hospital-based neonatology and maternal-fetal care can support consistent profitability even if overall volumes stay flat. The key near term catalyst is whether management can deliver on its 2026 adjusted EBITDA guidance of US$280 million to US$300 million after missing non GAAP earnings expectations. The biggest current risk is ongoing labor and incentive compensation pressure, which can quickly eat into margins if revenue growth remains modest.

    The most relevant recent announcement is Pediatrix’s 2025 earnings, which confirmed a swing back to full-year profitability with net income of US$165.39 million on US$1.91 billion of revenue. That result, alongside the updated 2026 EBITDA outlook and ongoing share repurchases under multiple buyback programs, frames how much room the company has to absorb wage inflation and practice restructuring without undermining its profitability targets.

    Yet beneath this recovery, investors should be aware that growing labor costs and physician shortages could still...

    Read the full narrative on Pediatrix Medical Group (it's free!)

    Pediatrix Medical Group's narrative projects $2.1 billion revenue and $145.1 million earnings by 2028. This requires 2.5% yearly revenue growth and a $35.2 million earnings increase from $109.9 million today.

    Uncover how Pediatrix Medical Group's forecasts yield a $22.67 fair value, a 15% upside to its current price.

    Exploring Other Perspectives

    MD 1-Year Stock Price Chart
    MD 1-Year Stock Price Chart

    Before this report, the most optimistic analysts were assuming revenue would reach about US$2.2 billion and earnings US$159 million, yet if labor costs and reimbursement pressures persist, you may find their bullish view very different from your own expectations.

    Explore 4 other fair value estimates on Pediatrix Medical Group - why the stock might be worth over 2x more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Contemplating Other Strategies?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.